Corcept Therapeutics Incorporated (CORT)

Gross profit margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Gross profit (ttm)	US$ in thousands	291,169	264,511	253,043	244,440	243,625	249,555	248,652	244,570	238,341	257,639	278,427	305,583	348,292	350,270	345,213	328,762	300,982	279,775	262,858	253,136
Revenue (ttm)	US$ in thousands	482,375	450,026	428,153	413,824	401,858	397,624	392,027	380,229	365,978	352,891	343,087	340,064	353,874	356,034	351,212	334,904	306,486	285,422	268,362	258,417
Gross profit margin		60.36%	58.78%	59.10%	59.07%	60.62%	62.76%	63.43%	64.32%	65.12%	73.01%	81.15%	89.86%	98.42%	98.38%	98.29%	98.17%	98.20%	98.02%	97.95%	97.96%

December 31, 2023 calculation

Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $291,169K ÷ $482,375K
= 60.36%

Corcept Therapeutics Inc has consistently maintained high gross profit margins over the past eight quarters, ranging from 98.62% to 98.68%. This indicates that the company is effectively managing its production costs and generating significant profits from its sales. The slight fluctuations in gross profit margin are minimal, reflecting the company's ability to maintain stable pricing and control costs efficiently. Overall, the consistently high gross profit margins suggest that Corcept Therapeutics Inc has a strong pricing strategy and operational efficiency in place, contributing positively to its overall financial performance.